Bio-Rad Laboratories Inc (NYSE:BIO)
$ 330.53 2.17 (0.66%) Market Cap: 9.23 Bil Enterprise Value: 9.00 Bil PE Ratio: 0 PB Ratio: 1.24 GF Score: 78/100

Bio Rad Laboratories Inc at Citi Healthcare & Medtech Conference Transcript

Mar 02, 2023 / 04:45PM GMT
Release Date Price: $502.79 (+5.76%)
Patrick Bernard Donnelly
Citigroup Inc., Research Division - Senior Analyst

All right. We will look to get started here. Thanks, everyone, for joining us. I'm Patrick Donnelly, the tools and diagnostics analyst here at Citi. Happy to have the Bio-Rad team; Ilan, the CFO; Norman, the CEO with us today. A lot to go through and maybe we can start just on the recent results, the guidance. The guidance was particularly healthy. But maybe we start on 4Q, you guys had some headwinds with things like supply chain that I know held you back, kind of the backlog is obviously quite healthy going to '23. Maybe start with just the moving pieces on 4Q, and we can work our way into the '23 guide that you guys provided, just a week or 2 ago there?

Questions & Answers

Ilan Daskal
Bio-Rad Laboratories, Inc. - Executive VP & CFO

Sure. I'll start there. Obviously, the supply chain constraints were challenging during 2022 for us. So it took us a little bit longer to overcome some of these challenges. If you recall at the beginning of the pandemic, it was more about

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot